Archive

Dive into a collection of past posts and rediscover timeless content.

A Medicare Insurer Just Beat EPS by 450% and Its Customer Acquisition Cost Dropped 14%

A 450% EPS beat and record unit economics from a Medicare insurance distributor. See if the improved cost efficiency makes this small-cap stock worth adding now.

May 16, 2026

Undervalued Edge

A Global Bank Just Posted Record Quarterly Profit and the Setup Still Looks Cheap

A major bank just posted record quarterly profit of €3.6 billion and pushed its capital ratio to 14.4%. Here’s why the valuation still has room to catch up.

May 15, 2026

Undervalued Edge Analysis

This Home Health Company Sold a Division for $811M and Raised Full-Year Guidance the Same Week

This home health company beat Q1 estimates, raised guidance, and closed an $811M asset sale in the same quarter. Find out if the setup makes it worth adding.

May 12, 2026

Undervalued Edge

The Biggest Payments Network Nobody Is Talking About Trades at a Deep Discount

This payment name trades at 8x earnings while peers average 30x. The business is still growing, and the valuation gap is hard to explain away. Read this now.

May 11, 2026

Undervalued Edge Analysis

This Domain Giant Just Cut Support Costs With AI and Expanded Margins to 33%

A web services company just hit 33% EBITDA margins and launched an AI builder with real revenue already. See if the margin story makes this worth adding now.

May 9, 2026

Undervalued Edge

This Steel Giant Is Up 28% in a Month With Earnings Estimates Still Climbing Higher

Rising estimates and reshoring tailwinds are all stacking up for one steel name right now. You want to know how much runway is left in this one.

May 8, 2026

Undervalued Edge Analysis

The Auto Supplier Pivoting Into Drones, Defense, and Alternative Fuels Just Beat Earnings

An auto parts supplier just won a defense drone contract and beat Q1 earnings by 14%. See if the diversification makes this industrial worth sizing into.

May 5, 2026

Undervalued Edge

Two Analyst Upgrades and a Summer Data Window Just Put This Biotech Back in Play

Two upgrades, two higher price targets, and a summer full of clinical readouts just put this biotech back on the watchlist. Here’s what the data calendar looks like.

May 4, 2026

Undervalued Edge Analysis

This Investment Bank Just Reported $1.4B in Revenue and Returned $673M to Shareholders

Revenue doubled year over year, and EPS beat by 39%. See if this investment bank’s surge in deal flow makes it worth adding to your portfolio now.

May 2, 2026